Therapeutic Drug Monitoring of Digoxin: Impact of Endogenous and Exogenous Digoxin-Like Immunoreactive Substances
Author: Dasgupta, Amitava1
Source: Toxicological Reviews, Volume 25, Number 4, 2006 , pp. 273-281(9)
Publisher: Adis International
- Free Content
- New Content
- Subscribed Content
- Free Trial Content
Abstract:
Digoxin is a cardioactive drug with a narrow therapeutic range. Therapeutic drug monitoring is essential in clinical practice for efficacy as well as to avoid digoxin toxicity. Immunoassays are commonly used in clinical laboratories for determination of serum or plasma digoxin concentrations. Unfortunately, digoxin immunoassays are affected by both endogenous and exogenous compounds. Endogenous compounds are termed `digoxin-like immunoreactive substances' (DLIS), which are found in elevated concentrations in volume-expanded patients. Exogenous compounds that interfere with digoxin assays are various drugs such as spironolactone, potassium canrenoate as well as Digibind® (Fab fragment of antidigoxin antibody), which is used in treating life-threatening digoxin overdose. Moreover, various Chinese medicines such as Chan Su, Lu-Shen Wan and oleander-containing herbal preparations also interfere with serum digoxin measurements by immunoassays. Monitoring unbound (free) digoxin concentration may under certain circumstances eliminate such interferences. Clinicians should be aware of limitations of therapeutic drug monitoring of digoxin using immunoassays.Keywords: Alternative medicine; Canrenoic acid; Canrenone; Children; Complementary and alternative medicine; Cross reactivity; Digoxin; Drug monitoring; Ginseng; Spironolactone
Document Type: Review article
Affiliations: 1: Department of Pathology and Laboratory Medicine, University of Texas-Houston Medical School, Houston, Texas, USA
- Free Content
- New Content
- Subscribed Content
- Free Trial Content
Click here for Page Help